April 30, 2026
2 min watch
Key takeaways:
- Mean IOP decreased from 16 mm Hg at baseline to approximately 14 mm Hg.
- Medication burden decreased from 1.25 to 0.75.
WASHINGTON — At 2 years, trabecular micro-bypass implantation in combination with phacoemulsification yielded IOP reductions in patients with open-angle glaucoma, according to a presenter.
At the American Society of Cataract and Refractive Surgery meeting, Zachary D. Vest, MD, of Mile High Eye Institute, told Healio that the iStent infinite (Glaukos) with phacoemulsification was evaluated in an unmasked, nonrandomized, retrospective, consecutive study in a consistent cohort of 27 eyes that had 24-month data.
According to Vest, mean IOP decreased from 16 mm Hg at baseline to approximately 14 mm Hg. There was also a reduction in medication burden.
“The medication burden decreased from 1.25 medications down to 0.75 medications on average,” he told Healio. “Approximately 93% of patients had a pressure less than 18 mm Hg at the completion of the 2 years.”
The complication rate was low, with no reported intraocular complications or secondary interventions related to adverse events, Vest said.
“Overall, this study showed good IOP reduction even in a study population starting out with a lower intraocular pressure than a normal MIGS study. There was a good decrease in overall medication requirements and a low risk of secondary intervention at 2 years,” Vest told Healio.
Sources/Disclosures
Source:
Vest ZD, et al. Two year outcomes after third-generation trabecular micro-bypass performed with phacoemulsification in patients with open-angle glaucoma. Presented at: American Society of Cataract and Refractive Surgery meeting; April 10-13, 2026; Washington.
Disclosures:
Vest reports consulting for and receiving research funding from Alcon and Glaukos.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply